Gilead Sciences, Inc. (NASDAQ:GILD) EVP Brett A. Pletcher sold 2,950 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $69.32, for a total value of $204,494.00. Following the completion of the sale, the executive vice president now owns 27,640 shares of the company’s stock, valued at $1,916,004.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Gilead Sciences stock opened at $66.80 on Friday. The company has a market capitalization of $84.51 billion, a PE ratio of 15.87, a price-to-earnings-growth ratio of 4.92 and a beta of 1.21. The company has a debt-to-equity ratio of 1.11, a quick ratio of 3.01 and a current ratio of 3.23. Gilead Sciences, Inc. has a fifty-two week low of $60.89 and a fifty-two week high of $71.19. The firm has a 50 day moving average price of $65.10 and a 200 day moving average price of $64.96.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $1.30 EPS for the quarter, missing the consensus estimate of $1.67 by ($0.37). Gilead Sciences had a return on equity of 35.49% and a net margin of 23.99%. The firm had revenue of $5.88 billion for the quarter, compared to analysts’ expectations of $5.74 billion. During the same quarter in the prior year, the business earned $1.44 earnings per share. The company’s quarterly revenue was up 1.4% on a year-over-year basis. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 6.12 earnings per share for the current year.
GILD has been the subject of a number of recent research reports. Sanford C. Bernstein downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $78.00 to $70.00 in a research note on Thursday, February 6th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Gilead Sciences in a report on Wednesday, February 5th. Guggenheim lowered shares of Gilead Sciences from a “buy” rating to a “neutral” rating in a report on Tuesday, January 21st. Piper Sandler cut their price objective on shares of Gilead Sciences from to in a research report on Wednesday, February 5th. Finally, Robert W. Baird set a $76.00 target price on shares of Gilead Sciences and gave the stock a “hold” rating in a research note on Friday, October 25th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $77.79.
Institutional investors have recently made changes to their positions in the stock. Knuff & Co LLC grew its holdings in Gilead Sciences by 2.3% during the 3rd quarter. Knuff & Co LLC now owns 34,310 shares of the biopharmaceutical company’s stock worth $2,175,000 after acquiring an additional 770 shares in the last quarter. AMG National Trust Bank lifted its position in shares of Gilead Sciences by 8.5% during the 4th quarter. AMG National Trust Bank now owns 74,817 shares of the biopharmaceutical company’s stock worth $4,862,000 after purchasing an additional 5,861 shares during the last quarter. S.A. Mason LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter worth $60,000. Ackerman Capital Advisors LLC grew its stake in shares of Gilead Sciences by 71.4% during the fourth quarter. Ackerman Capital Advisors LLC now owns 6,000 shares of the biopharmaceutical company’s stock worth $390,000 after purchasing an additional 2,500 shares in the last quarter. Finally, Fulcrum Capital LLC acquired a new position in shares of Gilead Sciences during the third quarter worth $9,804,000. Institutional investors own 79.26% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.